Conferences
Conferences
Advertisement
Koichiro Kimura, MD, PhDRLT | July 8, 2025
Dr. Kimura shares insights on PSMA PET/CT metrics and their potential role in guiding treatment decisions for mCRPC.
View More
Axel Bex, MD, PhDLocalized Renal Cell Carcinoma | July 1, 2025
Professor Bex discusses the phase II NEOAVAX trial that evaluated avelumab/axitinib as neoadjuvant therapy in localized RCC.
Samer Srour, MBAdvanced Renal Cell Carcinoma | June 30, 2025
Samer Srour, MB, talks about the updated ALLO-316 and its use in targeting CD70 in patients with advanced ccRCC.
Robert Flavell, MD, PhDRLT | June 27, 2025
Dr. Flavell discusses how landmark studies have shaped current trial designs, and growing interest in combination therapies.
Robert Flavell, MD, PhDRLT | June 27, 2025
Dr. Flavell highlights the expansion of lutetium PSMA therapies into earlier disease settings: HSPC and oligometastatic PC.
Emily MenendezProstate Cancer Diagnostics | June 25, 2025
Preliminary trial data suggests that 18F-DCFPyL PSMA PET/CT combined with mpMRI may improve csPCA detection over MRI alone.
Emily MenendezRLT | June 25, 2025
Quantitative analysis outperformed visual analysis in the prediction of outcomes for patients undergoing Lu-PSMA therapy.
Jessica GangaRLT | June 25, 2025
New research explores the prognostic potential of LuPSMA-SPECT/CT with RECIP 1.0 in patients with advanced prostate cancer.
Jessica GangaProstate Cancer Diagnostics | June 25, 2025
Researchers investigated the use of PSMA PET-CT to determine treatment options for patients with biochemical failure in PC.
Emily MenendezProstate Cancer Diagnostics | June 25, 2025
18F-fluciclovine PET detected disease in more than half of the study’s patients with BCR and negative PSMA PET results.
Jessica GangaTesticular, Penile, and Rare Malignancies | June 20, 2025
Researchers investigated the efficacy of platinum plus 5-FU in the treatment of patients with high-risk penile cancer.
Gerhardt Attard, MD, PhDmCSPC | June 20, 2025
Dr. Attard explores how the study's results compare with prior data in the metastatic castration-resistant setting.
Jessica GangaAdvanced Urothelial Carcinoma | June 17, 2025
Avelumab plus sacituzumab govitecan may improve PFS in patients with advanced bladder cancer.
Emily MenendeznccRCC | June 12, 2025
At 12 months, the OS rate for patients who received treatment with ipilimumab plus nivolumab was superior to SOC.
Karine Tawagi, MDProstate Cancer | June 12, 2025
The Two Onc Docs review QOL related to doublet ADT with darolutamide, niraparib with abiraterone for mCSPC, and more.
Karine Tawagi, MDRenal Cell Carcinoma | June 12, 2025
The Two Onc Docs review the 5-year follow-up data on adjuvant pembro and a final analysis on ipi/nivo for metastatic disease.
Karine Tawagi, MDUrothelial Carcinoma | June 12, 2025
The Two Onc Docs weigh IO for BCG-refractory NMIBC, ctDNA monitoring for patients receiving gem/cis for MIBC, and more.
Marc Machaalani, MDRenal Cell Carcinoma Diagnostics | June 11, 2025
Dr. Machaalani highlights his study that evaluated the association between circulating KIM-1 and mRCC tumor biology.
Nicholas James, PhDLocalized | June 9, 2025
Dr. James showcases an MMAI model to identify benefit from 2nd-generation ARPIs in hr/nm PCa patients from STAMPEDE.
Andrea Necchi, MDMuscle Invasive Urothelial Carcinoma | June 9, 2025
Drs. Necchi and Tawagi break down in detail the first results of SURE-02 in patients with muscle-invasive bladder cancer.
Advertisement
Advertisement